Back

Anti-CD38-Targeted Piperazine-Derived Lipid Nanoparticles Overcome Hepatic Clearance for mRNA Delivery to Multiple Myeloma Cells In Vivo

Figueroa-Espada, C. G.; Geisler, H. C.; Joseph, R. A.; Ricciardi, A. S.; Metzloff, A. E.; Acosta-Gonzalez, J. O.; Xue, L.; Yamagata, H. M.; Thatte, A. S.; MITCHELL, M. J.

2025-11-13 bioengineering
10.1101/2025.11.12.687398 bioRxiv
Show abstract

Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal heterogeneity, immune evasion, and therapeutic resistance. Messenger RNA (mRNA) therapeutics offer programmable strategies to express therapeutic proteins and gene editors, but their efficacy is limited by poor extrahepatic delivery. To overcome these barriers, we developed a lipid nanoparticle (LNP) platform for targeted mRNA delivery to MM cells in vivo. Through combinatorial screening, we identified C16-O1, a piperazine-based ionizable lipid that efficiently transfects both CD138+ and therapy-resistant CD138-MM subclones. For tumor selectivity, LNPs were functionalized with an antibody fragment against CD38, a clinically validated MM antigen. Anti-CD38 LNPs reached the tumor-site and significantly reduced hepatic accumulation in murine xenografts. As an in vitro proof-of-concept, delivery of Cas9 mRNA and an IRF4-targeting guide RNA induced gene knockout, cell-cycle arrest, and lenalidomide sensitization. Together, these findings establish a robust framework for targeted mRNA delivery in MM and other hematologic malignancies.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
ACS Central Science
● 71 papers in training set
Top 0.1%
8.5%
Similar papers in this journal
2
Advanced Science
○ 286 papers in training set
Top 0.8%
6.5%
Similar papers in this journal
3
Advanced Healthcare Materials
○ 85 papers in training set
Top 0.3%
6.0%
Similar papers in this journal
4
Journal of Controlled Release
○ 44 papers in training set
Top 0.2%
6.0%
Similar papers in this journal
5
Nature Communications
○ 5641 papers in training set
Top 28%
5.3%
Similar papers in this journal
6
Advanced Functional Materials
○ 46 papers in training set
Top 0.2%
4.9%
7
ACS Nano
● 113 papers in training set
Top 0.5%
4.7%
8
Angewandte Chemie International Edition
○ 93 papers in training set
Top 0.3%
4.1%
9
Science Advances
● 1243 papers in training set
Top 9%
3.9%
10
Nano Letters
● 71 papers in training set
Top 0.3%
3.9%
50% of probability mass above
11
Journal of the American Chemical Society
● 217 papers in training set
Top 1%
3.1%
12
Nature Nanotechnology
○ 32 papers in training set
Top 0.2%
3.1%
13
ACS Chemical Biology
● 167 papers in training set
Top 1%
2.7%
14
Bioconjugate Chemistry
● 20 papers in training set
Top 0.1%
2.7%
15
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.3%
2.5%
16
Nature Biotechnology
○ 172 papers in training set
Top 2%
2.0%
17
Advanced Materials
○ 56 papers in training set
Top 0.7%
1.7%
18
Molecular Therapy
○ 81 papers in training set
Top 1.0%
1.7%
19
Small
○ 78 papers in training set
Top 1%
1.4%
20
Advanced Therapeutics
○ 17 papers in training set
Top 0.2%
1.4%
21
Bioengineering & Translational Medicine
○ 21 papers in training set
Top 0.4%
1.1%
22
Nature Chemistry
○ 42 papers in training set
Top 0.7%
1.1%
23
Cell Chemical Biology
○ 94 papers in training set
Top 1%
1.1%
24
Molecular Pharmaceutics
● 16 papers in training set
Top 0.3%
1.1%
25
Cell Reports Medicine
○ 153 papers in training set
Top 4%
1.0%
26
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 39%
1.0%
27
Nature Biomedical Engineering
○ 47 papers in training set
Top 2%
0.9%
28
ACS Applied Materials & Interfaces
● 39 papers in training set
Top 1%
0.8%
29
Biomaterials
○ 84 papers in training set
Top 2%
0.8%
30
Chemical Science
● 73 papers in training set
Top 2%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.